



# Ronald Goldenberg MD, FRCPC, FACE

\* Ronald Goldenberg provides medical services through Dr. Ronald Goldenberg Medicine Professional Corporation

Thornhill 1600 Steeles Avenue West, Unit 5-10, Concord, Ontario, L4K 4M2, Canada

Tel (905) 763-8660

## CURRICULUM VITAE

### Education, Certification & Licenses

2018-2020	ICH-GCP Training Certificate	TransCelerate
1997	Fellowship	American College of Endocrinology
1989	Certification, Endocrinology & Metabolism	Royal College of Physicians & Surgeons, American Board of Internal Medicine
1988	Fellowship	Royal College of Physicians & Surgeons of Canada
1987	Certification, Internal Medicine	Royal College of Physicians & Surgeons, American Board of Internal Medicine
1989	Residency	University of Toronto, Toronto ON
1984	Doctor of Medicine, with honors	University of Toronto, Toronto ON

### Professional Activities

2017-Present	Sub-Investigator	LMC Clinical Research Inc.
1999-Present	Principal Investigator	LMC Clinical Research Inc.
1999-Present	Associate Endocrinologist	LMC Diabetes & Endocrinology
1989-Present	Staff Endocrinologist	North York General Hospital, Toronto ON
2010-2015	Steering Committee Member & Author, CDA 2013 Clinical Practice Guidelines	Canadian Diabetes Association (CDA)
2010-2016	Councillor, CDA Clinical & Scientific Section Executive Committee	Canadian Diabetes Association (CDA)
2001-2003	Diabetes Education Centre, Medical Director	North York General Hospital, Toronto ON
1991-2003	Diabetes Education Center, Medical Director	North York General Hospital, Branson Division, Toronto ON
1999-2002	Chair, Section on Endocrinology and Metabolism	Ontario Medical Association
1996-2002	Chair	Ontario Association of Endocrinologists
1998-99	Co-Chair, Section on Endocrinology and Metabolism	Ontario Medical Association

### Publications\*

Sodium-glucose cotransporter 2 inhibitors and type 2 diabetes: clinical pearls for in-hospital initiation, in-hospital management, and postdischarge. C. David Mazer, Amel Arnaout, Kim A. Connelly, Jeremy D. Gilbert, Stephen A. Glazer, Subodh Verma and **Ronald M. Goldenberg**. *Curr Opin Cardiol*. 2020; 35(2):178-186

Effect of Empagliflozin on Erythropoietin Levels, Iron Stores and Red Blood Cell Morphology in Patients with Type 2 Diabetes and Coronary Artery Disease. C. David Mazer, Gregory M. T. Hare, Philip W. Connelly, Richard E. Gilbert, Nadine Shehata, Adrian Quan, Hwee Teoh, Lawrence A. Leiter, Bernard Zinman, Peter Juni, Fei Zuo, Nikhil Mistry, Kevin E. Thorpe, **Ronald M. Goldenberg**, Andrew T. Yan, Kim A. Connelly, Subodh Verma. *Circulation*. 2019; <https://doi.org/10.1161/CIRCULATIONAHA.119.044235>

Patient Reported Outcomes following initiation of Glucagon-like peptide-1 Receptor agonists in patients with type 2 Diabetes in a specialist endocrinology practice of the LMC diabetes registry: The PROGRESS-Diabetes study. Ruth E. Brown, Alexander Abitbol, Harpreet S. Bajaj, **Ronald Goldenberg**, Hasnain Khandwala, Suzan Abdel-Salam, Ronnie Aronson. *Diabetes Research and Clinical Practice*. 2019; 156: <https://doi.org/10.1016/j.diabres.2019.107820>

Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA- HEART CardioLink-6 Randomized Clinical Trial. Subodh Verma, C. David Mazer, Andrew T. Yan, Tamique Mason, Vinay Garg, Hwee Teoh, Fei Zuo, Adrian Quan, Michael E. Farkouh, David H. Fitchett, Shaun G. Goodman, **Ronald M. Goldenberg**, Mohammed Al-Omran, Richard E. Gilbert, Deepak L. Bhatt, Lawrence A. Leiter, Peter Juni, Bernard Zinman, and Kim A. Connelly. *Circulation*. 2019; 140(21):1693-1702

Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol. **Ronald M Goldenberg**, Jeremy D Gilbert, Irene M Hramiak, Vincent C Woo, Bernard Zinman. *Diabetes Obes Metab*. 2019; 21(10):2192-2202

Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials. Robert D. Toto, **Ronald Goldenberg**, Glenn M. Chertow, Valerie Cain, Bergur V. Stefansson, C. David Sjostrom, Peter Sartipy. *Journal of Diabetes and its Complications*. 2019; 33:107402

### Clinical Trials & Research Activities

2010-2020	TAK-875_304 (Takeda), NC25608B (Roche), M11-350 (Abbott), OpTmise (Medtronic), MB102-002 (BMS), DAPA 19 (BMS), 28431754-DIA-2004 (J&J), NN1250-3718 (NovoNordisk), 28431754-DIA-3012 (J&J), EFC 6016 (Sanofi-aventis), EFC 6017 (Sanofi-aventis), MB102-013 (BMS), MB102-014 (BMS), 1245.36 (BI), EFC 10781 (Sanofi-aventis), EMERGE 6 (Roche), CACZ 2207 (Novartis), AZ L0006 (AstraZeneca), REWIND (Eli Lilly), EFC 11628 & 12261 (Sanofi-aventis), TAK-875_306 (Takeda), EFC12347 (Sanofi-aventis), EFC12456 (Sanofi-aventis), RGN1110 (Regeneron), RGN1118 (Regeneron), DECLARE 58 (AstraZeneca), TAK-875_309 (Takeda), MK3102-026 (Merck), MOT114479 (GSK), BMS010 (BMS), B1481022 (Pfizer), B1481038 (Pfizer), B1521022 (Pfizer), GSN000200 (Genkyotex), INNOVATE (LMC Diabetes & Endocrinology), NN9211-3919 (Novo Nordisk), NN9211-4083 (Novo Nordisk), MK8835-002 (Merck), APD356-G000-401 (Eisai), NN9211-3919(Novo), EFC12404/405(Sanofi-aventis), CREDENCE (Janssen), STRENGTH (AstraZeneca), EFC13799 (Sanofi-aventis), B1481045 (Pfizer), HARMONY 10 (GSK), J&J 2004 (Janssen), PERL (Joslin Diabetes Center), LX4211.309 (Lexicon), DERIVE (AstraZeneca), LX4211.312 (Lexicon), DIAMOND (Dexcom), B4801010 (Pfizer), Onset 5 (Novo Nordisk), Onset 8 (Novo Nordisk), Pioneer 6 (Novo Nordisk), LPS14347 (Sanofi), D169AC00001 (AstraZeneca), EFC14834 (Sanofi), MSC15146 (Sanofi), MK-0431-845 (Merck), Onset 9 (Novo Nordisk), K-877-302 (KOWA), Remit-Sita (PHRI), D5670C00004 (AstraZeneca), EFC14828 (Sanofi), CAN-TREAT (Novo Nordisk), EFC15294 (Sanofi), EFC14837 (Sanofi), EFC14875 (Sanofi), CEMA401A2202 (Novartis), NN1436-4383 (Novo Nordisk), OBS16040 (Sanofi), EMPA-KIDNEY (UBC), I8F-MC-GPGM (Eli Lilly), LPS15544 (Sanofi), NN9536-4374 (Novo Nordisk), NN1250-4419 (Novo Nordisk), TRCA-303 (Tricida), I8B-MC-ITRO (Eli Lilly), NN1436-4466 (Novo Nordisk), EX9924-4473 (Novo Nordisk), NN9535-4321 (Novo Nordisk), NN9535-4352 (Novo Nordisk), GS-US-223-1017 (Gilead), 20170625 (Amgen), etc.
1998-2009	Rio DM (Sanofi-aventis), MKC-TI-030 (Mannkind), MK 0431-052 (Merck), A5351022(Pfizer), Smooth (BI), Disocvery (AstraZeneca), 3012 (Aventis), RASS (M.Sinai), P00693 (Schering-Plough), Piglitazone (Eli Lilly), Epleronone 023 (Searle), BIG (Bayer), Hypertri g(Bayer),GM-611 (Chugai),ZD4522-081 (AstraZeneca), Mercury 1 (AstraZeneca), IOME (Eli Lilly), Avandia/Amaryl (GSK), IDAP (Eli Lilly), CV131-185 (BI), CV131-176 (BMS), NN 304-2175 (NovoNordisk), ALISKIREN (NovoNordisk), Rio Lipids(Sanofi-aventis), Eperonone 021(Searle), Topiramate (J&J), CHOIR (Bayer), Micardis (GlaxoWellcome), MATCHED (Medicure), P00692 (Schering-Plough), Polaris (AstraZeneca), Navigator(Novartis), ENDORSE (Servier), TREAT (Amgen), MARS 228 (Eisai), EFC 6910 (Sanofi-aventis), LANTU (Sanofi-aventis), Cresendo (Sanofi-aventis), MKC-TI-102(Mannkind), MKC-TI-009 (Mannkind), MKC-TI-103 (Mannkind), MKC-TI-126 (Mannkind), MARS 227 (Eisai), AXON (TransTech Pharma), CACZ 2308 (Novartis), NERV (J&J), CL-503011 (Bellus Health), MO5-748 (Abbott), MO5-758 (Abbott), TIDE (GSK), STABILITY (GSK), EMERGE 4 (Roche), EFC 10780 (Sanofi-aventis), AS3201-291 (Eisai), MB102-029 (BMS), CLAF 2201 (Novartis), AZ06 (AstraZeneca), CLAF 2224 (Novartis), V3381 (Vernalis), AS3201-G000-291(Eisai), CV-181-011 (BMS) ALTITUDE (Novartis), etc.

\*>40 Publications; Principal Investigator on 150+ clinical trials